Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Amgen Posts Higher 1Q Revenue, Swings to Loss
Hillhouse Boosts Longi Position After Robe, As It Pivots To Global Focus
Hillhouse Boosts Longi Position After Robe, As It Pivots To Global Focus
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
BeiGene (BGNE) Receives a Hold from Bernstein
BeiGene (BGNE) Receives a Hold from Bernstein
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment
With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners
With 42% ownership of the shares, BeiGene, Ltd. (NASDAQ:BGNE) is heavily dominated by institutional owners
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Shareholders in BeiGene (NASDAQ:BGNE) have lost 54%, as stock drops 8.5% this past week
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE) and BeiGene (BGNE)
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.